More recently, the EGFR-targeted antibody-drug conjugate (ADC) MRG003 has demonstrated an ORR of 55.2% in a phase 2a study of patients with r/m NPC whose disease had failed prior platinum and/or PD-1 therapy [56]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.